NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
For more than 50 years, low-cost antimalarial drugs silently saved millions of lives and cured billions of debilitating infections. Today, however, these drugs no longer work against the deadliest form of malaria that exists throughout the world. Malaria deaths in sub-Saharan Africa—currently just over one million per year—are rising because of increased resistance to the old, inexpensive drugs. Although effective new drugs called “artemisinins” are available, they are unaffordable for the majority of the affected population, even at a cost of one dollar per course.
Saving Lives, Buying Time: Economics of Malaria Drugs in an Age of Resistance examines the history of malaria treatments, provides an overview of the current drug crisis, and offers recommendations on maximizing access to and effectiveness of antimalarial drugs. The book finds that most people in endemic countries will not have access to currently effective combination treatments, which should include an artemisinin, without financing from the global community. Without funding for effective treatment, malaria mortality could double over the next 10 to 20 years and transmission will intensify.
Contents
- THE NATIONAL ACADEMIES
- COMMITTEE ON THE ECONOMICS OF ANTIMALARIAL DRUGS
- BOARD ON GLOBAL HEALTH
- Reviewers
- Preface
- Acknowledgments
- PROJECT CONSULTANTS AND COMMISSIONED AUTHORS
- Executive Summary
- INTRODUCTION
- THE CURRENT MALARIA SITUATION
- DRUG RESISTANCE AND THE NEED FOR COMBINATION THERAPY FOR MALARIA
- THE ECONOMICS OF ARTEMISININS AND ACTs
- THE CASE FOR A GLOBAL SUBSIDY FOR ANTIMALARIAL DRUGS: THE CORE RECOMMENDATION OF THIS REPORT
- THE NEED TO MAINTAIN RESEARCH AND DEVELOPMENT FOR NEW ANTIMALARIAL DRUGS
- IMPROVING ACCESS AND THE PROMISE OF INTEGRATED MALARIA CONTROL
- THE CURRENT CHOICE
- RECOMMENDATIONS
- PART 1. A Response to the Current Crisis
- 1. Malaria Today
- 2. The Cost and Cost-Effectiveness of Antimalarial Drugs
- The Immediate Problem of ACT Affordability
- The Cost of Producing ACTs and Future Prices
- The Global Cost of ACTs and Future Antimalarials
- COST-EFFECTIVENESS OF ACTs AND OTHER ANTIMALARIAL DRUGS
- CURRENT LEVELS OF GLOBAL FINANCING FOR MALARIA CONTROL
- PROJECTED FINANCING NEEDS FOR GLOBAL MALARIA CONTROL
- REFERENCES
- 3. The Case for a Global Subsidy of Antimalarial Drugs
- 4. An International System for Procuring Antimalarial Drugs
- PART 2. Malaria Basics
- 5. A Brief History of Malaria
- 6. The Parasite, the Mosquito, and the Disease
- 7. The Human and Economic Burden of Malaria
- 8. Malaria Control
- INTRODUCTION
- HISTORICAL OVERVIEW
- BASIC PRINCIPLES OF MALARIA CONTROL
- INSECTICIDES AND INSECTICIDE RESISTANCE
- INSECTICIDE-TREATED BEDNETS AND INDOOR RESIDUAL SPRAYING
- OTHER VECTOR CONTROL MEASURES
- TREATMENT AND CHEMOPREVENTION
- DIAGNOSTIC METHODS
- MALARIA VACCINES
- INTEGRATED CONTROL PROGRAMS AND SPECIAL SETTINGS
- MALARIA CONTROL PROGRAMS AND DRUG POLICIES
- CONCLUSION
- REFERENCES
- 9. Antimalarial Drugs and Drug Resistance
- PART 3. Advancing Toward Better Malaria Control
- Acronyms and Abbreviations
- Glossary
NOTICE: The project that is the subject of this report was approved by the Governing Board of the National Research Council, whose members are drawn from the councils of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine. The members of the committee responsible for the report were chosen for their special competences and with regard for appropriate balance.
This study was supported by Contract No. HRN-A-00-00-00012-00 between the National Academy of Sciences and the U.S. Agency for International Development (USAID) and the Bill and Melinda Gates Foundation. Any opinions, findings, conclusions, or recommendations expressed in this publication are those of the authors and do not necessarily reflect the views of the organizations or agencies that provided support for this project.
- NLM CatalogRelated NLM Catalog Entries
- Review Conquering the intolerable burden of malaria: what's new, what's needed: a summary.[Am J Trop Med Hyg. 2004]Review Conquering the intolerable burden of malaria: what's new, what's needed: a summary.Breman JG, Alilio MS, Mills A. Am J Trop Med Hyg. 2004 Aug; 71(2 Suppl):1-15.
- Social marketing and the fight against malaria in Africa: population services international (PSI) and insecticide treated nets (ITNS).[East Afr J Public Health. 2009]Social marketing and the fight against malaria in Africa: population services international (PSI) and insecticide treated nets (ITNS).Omona J. East Afr J Public Health. 2009 Dec; 6(3):317-25.
- Should new antimalarial drugs be subsidized?[J Health Econ. 2010]Should new antimalarial drugs be subsidized?Laxminarayan R, Parry IW, Smith DL, Klein EY. J Health Econ. 2010 May; 29(3):445-56. Epub 2010 Mar 7.
- Review Diagnosis and Treatment of the Febrile Child.[Reproductive, Maternal, Newbor...]Review Diagnosis and Treatment of the Febrile Child.Herlihy JM, D’Acremont V, Hay Burgess DC, Hamer DH. Reproductive, Maternal, Newborn, and Child Health: Disease Control Priorities, Third Edition (Volume 2). 2016 Apr 5
- Review Strategies to maintain health in the Third World.[Trop Med Parasitol. 1991]Review Strategies to maintain health in the Third World.Korte R, Rehle T, Merkle A. Trop Med Parasitol. 1991 Dec; 42(4):428-32.
- Saving Lives, Buying TimeSaving Lives, Buying Time
- Acknowledgements - ImmunoCAP® ISAC and Microtest for multiplex allergen testing ...Acknowledgements - ImmunoCAP® ISAC and Microtest for multiplex allergen testing in people with difficult to manage allergic disease: a systematic review and cost analysis
- Homo sapiens chromosome 19 open reading frame 81 (C19orf81), mRNAHomo sapiens chromosome 19 open reading frame 81 (C19orf81), mRNAgi|1653961064|ref|NM_001195076.2|Nucleotide
- ubiquitin carboxyl-terminal hydrolase CYLD isoform 1 [Homo sapiens]ubiquitin carboxyl-terminal hydrolase CYLD isoform 1 [Homo sapiens]gi|1819229346|ref|NP_001365672.1|Protein
Your browsing activity is empty.
Activity recording is turned off.
See more...